Bio-Techne

Read more
Charles R Kummeth's photo - President & CEO of Bio-Techne

President & CEO

Charles R Kummeth

CEO Approval Rating

69/100

Founded:

1981

Status:

PublicIndependent CompanyNASDAQTECH

BIO-TECHNE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

PeproTech is Bio-Techne's #1 competitor. PeproTech was founded in Rocky Hill, New Jersey} in 1988. PeproTech operates in the Health Care Supplies industry. Compared to Bio-Techne, PeproTech generates $767.8M less revenue.

CST is one of Bio-Techne's top competitors. CST was founded in 1999 in Danvers, Massachusetts. Like Bio-Techne, CST also competes in the Pharmaceuticals industry. CST generates $732.6M less revenue than Bio-Techne.

Abcam is a top competitor of Bio-Techne. Abcam was founded in 1998, and is headquartered in Cambridge, England. Like Bio-Techne, Abcam also operates in the Pharmaceuticals industry. Abcam generates $527.5M less revenue vs. Bio-Techne.

Bio-Techne Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$847.8M

Bio-Techne's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 19B. Over the last four quarters, Bio-Techne's revenue has grown by 38.5%. Specifically, in Q1 2021's revenue was $243.6M; in Q4 2020, it was $224.3M; in Q3 2020, it was $204.2M; in Q2 2020, Bio-Techne's revenue was $175.8M.

Bio-Techne Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Asuragen, Inc.

Mar 2021

Source »
$215M
Asuragen is a molecular diagnostic product company that provides oncology, and clinical testing services for cancer diagnosis.
B-MoGen Biotechnologies, Inc.

Jun 2019

Source »
undisclosed
B-MoGen provides gene editing solutions for immunotherapy treatments.
Quad Technologies, Inc.

Jun 2018

Source »
undisclosed
Quad is a developer and provider of cell separation and activation technology for cell and gene therapy applications.
Exosome Diagnostics, Inc.

Jun 2018

Source »
$250M
Exosome is focused on developing and commercializing biofluid-based diagnostics solutions to deliver personalized precision healthcare.

-

Scientific Ventures, Inc

Jan 2018

Source »
undisclosed
-

These are all the companies that Bio-Techne has acquired. Bio-Techne has acquired 14 companies and its latest acquisition was Asuragen, Inc. in Mar 2021. Asuragen is a molecular diagnostic product company that provides oncology, and clinical testing services for cancer diagnosis.

Bio-Techne Funding History

No recent funding data found related to Bio-Techne

Bio-Techne Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Eminence is a biotechnology company that develops and commercializes Chinese Hamster Ovary cells for the pharmaceutical industry.
-
Jan 27, 2021
Equity
-
Astute Medical identifies, develops and validates protein biomarkers that serve as the basis for in vitro diagnostic tests.
$43M
Dec 13, 2016
Equity
Apr 01, 2018
B-MoGen provides gene editing solutions for immunotherapy treatments.
$1M
May 01, 2016
Seed
Jun 01, 2019
CyVek develops a technology for measuring analyses in biological samples.
$10M
Apr 03, 2014
Equity
Nov 01, 2014

These are all the companies that Bio-Techne has invested in. Bio-Techne has invested 4 companies and its latest investment was Eminence in Jan 27,. Eminence is a biotechnology company that develops and commercializes Chinese Hamster Ovary cells for the pharmaceutical industry.

Bio-Techne News

Bio-Techne Press Releases

Bio-Techne Videos

Social Media

Bio-Techne Headquarters

614 McKinley Place NE

Minneapolis, Minnesota55413

1-612-379-2956

Driving Directions »

Trending Companies

Bio-Techne Summary

ABOUT

Overview

Bio-Techne is a biotechnology firm that develops, manufactures and sells biotechnology products, instruments and clinical diagnostic brands. Bio-Techne was founded in 1981. Bio-Techne's headquarters is located in Minneapolis, Minnesota, USA 55413. Bi...

CEO

Bio-Techne's President & CEO, Charles R Kummeth, currently has an approval rating of 69%. Bio-Techne's primary competitors are PeproTech, CST & Abcam.

Frequently Asked Questions about Bio-Techne

  1. When was Bio-Techne founded?

    Bio-Techne was founded in 1981
  2. Who is Bio-Techne's CEO?

    Bio-Techne's CEO is Charles R Kummeth
  3. How much revenue does Bio-Techne generate?

    Bio-Techne generates $847.8M in revenue
  4. How much funding does Bio-Techne have?

    Bio-Techne has historically raised $0 in funding
  5. Where is Bio-Techne's headquarters?

    Bio-Techne's headquarters is in Minneapolis Minnesota, USA
  1. How many employees does Bio-Techne have?

    Bio-Techne has 2,250 employees
  2. What sector does Bio-Techne operate in?

    Bio-Techne is in Pharmaceuticals
  3. Who are Bio-Techne's competitors?

    Bio-Techne's top competitors are PeproTech, CST, Abcam
  4. Who has Bio-Techne invested in?

    Bio-Techne's has invested in companies such as Eminence, Astute Medical, B-MoGen